Condition (MeSH)
Paget Disease, Extramammary
ClinicalTrials.gov lists 14 trials for Paget Disease, Extramammary or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
14 of the 14 trials are tagged with Paget Disease, Extramammary itself; the rest are tagged with a narrower condition beneath it.
When did Paget Disease, Extramammary trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 4 |
| 2024 | 3 |
| 2023 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2015 | 1 |
| 2009 | 1 |
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Paget Disease, Extramammary trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 9 |
| Phase 3 | 1 |
| Not applicable | 2 |
| Observational | 1 |
How many Paget Disease, Extramammary trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 10 |
| Active, not recruiting | 2 |
| Completed | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Paget Disease, Extramammary trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 2 |
Which drugs are being tested for Paget Disease, Extramammary? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| NIVOLUMAB | 2 |
| Trastuzumab Rezetecan | 1 |
| RC48 | 1 |
| IPILIMUMAB | 1 |
| PEMBROLIZUMAB | 1 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Disitamab Vedotin combined with Bicalutamide | 1 |
| Ivocizumab | 1 |
| Albumin paclitaxel injection | 1 |
| Disitamab Vedotin combined with Toripalimab | 1 |
| MQ719 | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Paget Disease, Extramammary? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The Paget Trial: topical 5% imiquimod cream for noninvasive vulvar Paget disease. | American journal of obstetrics and gynecology | 2022 | Yes |
| High Risk of Proximal and Local Neoplasms in 2206 Patients With Anogenital Extramammary Paget's Disease. | Diseases of the colon and rectum | 2019 | Yes |
| Vulvar skin disorders throughout lifetime: about some representative dermatoses. | BioMed research international | 2014 | Yes |
| Centennial paper. May 1912 (J Cutan Dis Syph 1912;30:241-255). Precancerous dermatoses: a study of two cases of chronic atypical epithelial proliferation. By John T. Bowen, M.D., Boston. | Archives of dermatology | 1983 | No |
| Carcinoma of the anus. | Annals of surgery | 1976 | No |
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Extramammary Paget disease | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Extramammary Paget disease | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Extramammary Paget disease | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Extramammary Paget disease | 2800 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Extramammary Paget disease | 2800 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.